Inclusion Criteria:

- metastatic adenocarcinoma of the colon or rectum

- wild-type KRAS tumor status

- radiographic evidence of disease progression during or following treatment with
irinotecan and/or oxaliplatin containing chemotherapy for mCRC

- measurable disease >/= 20 mm per RECIST

- ECOG 0 or 1

- adequate laboratory values

Exclusion Criteria:

- history of CNS metastases

- history of another primary cancer, unless:

- curatively resected non-melanomatous skin cancer

- curatively treated cervical carcinoma in situ

- other primary solid tumor treated with curative intent and no known active disease
present for >/= 5 years

- prior treatment with an anti-EGFR, c-MET, and/or IGFR inhibitor

- prior treatment with AMG 102 or AMG 479

- prior treatment with chemotherapy or radiotherapy
- prior treatment with targeted therapy
- known allergy or hypersensitivity to panitumumab, AMG 102, or AMG 479

- history of interstitial lung disease

- clinically significant cardiovascular disease
- active inflammatory bowel disease

- known HIV, hepatitis C, or hepatitis B infection

- any co-morbid disease or condition that could increase the risk of toxicity

- serious or non-healing wound
- any uncontrolled concurrent illness or history of any medical condition that could
interfere with the interpretation of the study results

- major surgical procedure
- other investigational procedures or drugs